Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

NYSE: JNJ

    • Home
    • NYSE: JNJ
    • Page 12
Company

Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance

Fineline Cube Oct 19, 2022

US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing...

Company Deals Digital

J&J China, Tencent Launch Digital Rhinitis Platform “Love Nose e-Station”

Fineline Cube Sep 2, 2022

Johnson & Johnson’s (J&J, NYSE: JNJ) J&J China Self Care and China’s Tencent have launched...

Company

J&J Q2 Sales Rise 8% but Profits Plunge 23% Amid China COVID Lockdowns

Fineline Cube Jul 20, 2022

US giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q2 2022 financials, showing 8.0% year-on-year...

Posts pagination

1 … 11 12

Recent updates

  • China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years
  • Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%
  • GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market
  • Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy
  • Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Company

Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%

Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Company Drug

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.